论文部分内容阅读
目的探讨MRI联合PSA检测在诊断前列腺癌骨转移中的应用价值。方法选择某院收入的前列腺癌患者共74例,患者入院后检测血清PSA水平及MRI情况,从而检测前列腺癌骨转移患者表达情况。结果所有74例患者中,前列腺癌骨转移阳性共43例(58.1%),PSA≥20μg/L组患者前列腺癌骨转移阳性率为69.6%,显著高于PSA﹤20μg/L组的22.2%,两组对比差异有统计学意义(P﹤0.05)。PSA≥20μg/L组敏感度显著高于PSA(μg/L)﹤20μg/L组,两组患者敏感性对比差异有统计学意义(P﹤0.05)。结论 PSA具有较好的预测前列腺癌骨转移的作用,当PSA≥20μg时,患者发生前列腺癌骨转移的概率显著增加。PSA≥20μg/L时再结合MRI检测,能显著提高前列腺癌骨转移的诊断水平。
Objective To investigate the value of MRI combined with PSA in diagnosis of bone metastasis of prostate cancer. Methods A total of 74 patients with prostate cancer from a hospital were enrolled in the study. Serum PSA levels and MRI were measured after admission to detect the expression of prostate cancer patients with bone metastases. Results In all 74 patients, the positive rate of prostate cancer bone metastasis was 43 (58.1%). The positive rate of prostate cancer bone metastasis was 69.6% in PSA≥20μg / L group, which was significantly higher than that in PSA 20μg / L group (22.2% The difference between the two groups was statistically significant (P <0.05). The sensitivity of PSA≥20μg / L group was significantly higher than that of PSA (μg / L) <20μg / L group, the difference was statistically significant (P <0.05). Conclusions PSA has a good predictive value for prostate cancer bone metastasis. When PSA≥20μg, the probability of prostate cancer bone metastasis is significantly increased. PSA ≥ 20μg / L combined with MRI detection, can significantly improve the diagnosis of prostate cancer bone metastases.